Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia

Saroj Vadhan-Raj, Shreyaskumar Patel, Carlos Bueso-Ramos, Jody Folloder, Nicholas Papadopolous, Andrew Burgess, Lyle D. Broemeling, Hal E. Broxmeyer, Robert S. Benjamin

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Purpose: Recombinant human thrombopoietin (rhTPO) increases platelets, and the peak response of rhTPO is delayed and is, therefore, not uniformly effective when administered after chemotherapy. The purpose of this study was to identify an effective schedule of rhTPO to best attenuate early thrombocytopenia. Patients and Methods: Cohorts of six patients with sarcoma (66 assessable patients) were treated sequentially with doxorubicin and ifosfamide (AI), with rhTPO by a fixed dose and varying schedules being administered before and/or after chemotherapy in cycle 2 and subsequent cycles. Cycle 1 without rhTPO served as an internal control. Results: AI causes cumulative thrombocytopenia. The platelet nadir in cycle 2 was higher than in cycle 1 (mean nadir ± SEM, 119 ± 12 × 103/μL v 80 ± 7 × 103/μL, respectively; P < .001) in 24 (80%) of the 30 patients (P < .001) in whom rhTPO (1.2 μg/kg) was administered starting from 5 days before chemotherapy (pre/postdoses, three/one or one/one) compared with only four (17%) of 24 patients given rhTPO by other schedules (pre/postdoses. two/two, one/three, zero/four, or four/zero) and none of 15 historical control patients. The need for platelet transfusions in four cycles was significantly lower (13 [11%] of 114 cycles, P < .001) in patients who received rhTPO from day -5 (pre/post doses, three/one or one/one) compared with patients who received rhTPO at later time points (28 [47%] of 60 cycles). Bone marrow megakaryocytes increased markedly (four-fold) before chemotherapy with predosing rhTPO and remained elevated (two-fold) after chemotherapy, which may explain the possible mechanism for response. One patient developed subclavian vein thrombosis, and no patients developed neutralizing antibodies to rhTPO. Conclusion: These results demonstrate the importance of timing of rhTPO in relation to chemotherapy and indicate that, by optimizing the timing, only two doses of rhTPO (one before and one after chemotherapy) were required to significantly reduce the severity of chemotherapy-related early thrombocytopenia.

Original languageEnglish (US)
Pages (from-to)3158-3167
Number of pages10
JournalJournal of Clinical Oncology
Volume21
Issue number16
DOIs
StatePublished - Aug 15 2003

Fingerprint

Thrombopoietin
Thrombocytopenia
Drug Therapy
Appointments and Schedules
Ifosfamide
Blood Platelets
Subclavian Vein
Platelet Transfusion
Megakaryocytes
Neutralizing Antibodies
Sarcoma
Doxorubicin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Vadhan-Raj, S., Patel, S., Bueso-Ramos, C., Folloder, J., Papadopolous, N., Burgess, A., ... Benjamin, R. S. (2003). Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. Journal of Clinical Oncology, 21(16), 3158-3167. https://doi.org/10.1200/JCO.2003.08.003

Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. / Vadhan-Raj, Saroj; Patel, Shreyaskumar; Bueso-Ramos, Carlos; Folloder, Jody; Papadopolous, Nicholas; Burgess, Andrew; Broemeling, Lyle D.; Broxmeyer, Hal E.; Benjamin, Robert S.

In: Journal of Clinical Oncology, Vol. 21, No. 16, 15.08.2003, p. 3158-3167.

Research output: Contribution to journalArticle

Vadhan-Raj, S, Patel, S, Bueso-Ramos, C, Folloder, J, Papadopolous, N, Burgess, A, Broemeling, LD, Broxmeyer, HE & Benjamin, RS 2003, 'Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia', Journal of Clinical Oncology, vol. 21, no. 16, pp. 3158-3167. https://doi.org/10.1200/JCO.2003.08.003
Vadhan-Raj, Saroj ; Patel, Shreyaskumar ; Bueso-Ramos, Carlos ; Folloder, Jody ; Papadopolous, Nicholas ; Burgess, Andrew ; Broemeling, Lyle D. ; Broxmeyer, Hal E. ; Benjamin, Robert S. / Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. In: Journal of Clinical Oncology. 2003 ; Vol. 21, No. 16. pp. 3158-3167.
@article{71d865b3fb9547dcade7e29da6197f68,
title = "Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia",
abstract = "Purpose: Recombinant human thrombopoietin (rhTPO) increases platelets, and the peak response of rhTPO is delayed and is, therefore, not uniformly effective when administered after chemotherapy. The purpose of this study was to identify an effective schedule of rhTPO to best attenuate early thrombocytopenia. Patients and Methods: Cohorts of six patients with sarcoma (66 assessable patients) were treated sequentially with doxorubicin and ifosfamide (AI), with rhTPO by a fixed dose and varying schedules being administered before and/or after chemotherapy in cycle 2 and subsequent cycles. Cycle 1 without rhTPO served as an internal control. Results: AI causes cumulative thrombocytopenia. The platelet nadir in cycle 2 was higher than in cycle 1 (mean nadir ± SEM, 119 ± 12 × 103/μL v 80 ± 7 × 103/μL, respectively; P < .001) in 24 (80{\%}) of the 30 patients (P < .001) in whom rhTPO (1.2 μg/kg) was administered starting from 5 days before chemotherapy (pre/postdoses, three/one or one/one) compared with only four (17{\%}) of 24 patients given rhTPO by other schedules (pre/postdoses. two/two, one/three, zero/four, or four/zero) and none of 15 historical control patients. The need for platelet transfusions in four cycles was significantly lower (13 [11{\%}] of 114 cycles, P < .001) in patients who received rhTPO from day -5 (pre/post doses, three/one or one/one) compared with patients who received rhTPO at later time points (28 [47{\%}] of 60 cycles). Bone marrow megakaryocytes increased markedly (four-fold) before chemotherapy with predosing rhTPO and remained elevated (two-fold) after chemotherapy, which may explain the possible mechanism for response. One patient developed subclavian vein thrombosis, and no patients developed neutralizing antibodies to rhTPO. Conclusion: These results demonstrate the importance of timing of rhTPO in relation to chemotherapy and indicate that, by optimizing the timing, only two doses of rhTPO (one before and one after chemotherapy) were required to significantly reduce the severity of chemotherapy-related early thrombocytopenia.",
author = "Saroj Vadhan-Raj and Shreyaskumar Patel and Carlos Bueso-Ramos and Jody Folloder and Nicholas Papadopolous and Andrew Burgess and Broemeling, {Lyle D.} and Broxmeyer, {Hal E.} and Benjamin, {Robert S.}",
year = "2003",
month = "8",
day = "15",
doi = "10.1200/JCO.2003.08.003",
language = "English (US)",
volume = "21",
pages = "3158--3167",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "16",

}

TY - JOUR

T1 - Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia

AU - Vadhan-Raj, Saroj

AU - Patel, Shreyaskumar

AU - Bueso-Ramos, Carlos

AU - Folloder, Jody

AU - Papadopolous, Nicholas

AU - Burgess, Andrew

AU - Broemeling, Lyle D.

AU - Broxmeyer, Hal E.

AU - Benjamin, Robert S.

PY - 2003/8/15

Y1 - 2003/8/15

N2 - Purpose: Recombinant human thrombopoietin (rhTPO) increases platelets, and the peak response of rhTPO is delayed and is, therefore, not uniformly effective when administered after chemotherapy. The purpose of this study was to identify an effective schedule of rhTPO to best attenuate early thrombocytopenia. Patients and Methods: Cohorts of six patients with sarcoma (66 assessable patients) were treated sequentially with doxorubicin and ifosfamide (AI), with rhTPO by a fixed dose and varying schedules being administered before and/or after chemotherapy in cycle 2 and subsequent cycles. Cycle 1 without rhTPO served as an internal control. Results: AI causes cumulative thrombocytopenia. The platelet nadir in cycle 2 was higher than in cycle 1 (mean nadir ± SEM, 119 ± 12 × 103/μL v 80 ± 7 × 103/μL, respectively; P < .001) in 24 (80%) of the 30 patients (P < .001) in whom rhTPO (1.2 μg/kg) was administered starting from 5 days before chemotherapy (pre/postdoses, three/one or one/one) compared with only four (17%) of 24 patients given rhTPO by other schedules (pre/postdoses. two/two, one/three, zero/four, or four/zero) and none of 15 historical control patients. The need for platelet transfusions in four cycles was significantly lower (13 [11%] of 114 cycles, P < .001) in patients who received rhTPO from day -5 (pre/post doses, three/one or one/one) compared with patients who received rhTPO at later time points (28 [47%] of 60 cycles). Bone marrow megakaryocytes increased markedly (four-fold) before chemotherapy with predosing rhTPO and remained elevated (two-fold) after chemotherapy, which may explain the possible mechanism for response. One patient developed subclavian vein thrombosis, and no patients developed neutralizing antibodies to rhTPO. Conclusion: These results demonstrate the importance of timing of rhTPO in relation to chemotherapy and indicate that, by optimizing the timing, only two doses of rhTPO (one before and one after chemotherapy) were required to significantly reduce the severity of chemotherapy-related early thrombocytopenia.

AB - Purpose: Recombinant human thrombopoietin (rhTPO) increases platelets, and the peak response of rhTPO is delayed and is, therefore, not uniformly effective when administered after chemotherapy. The purpose of this study was to identify an effective schedule of rhTPO to best attenuate early thrombocytopenia. Patients and Methods: Cohorts of six patients with sarcoma (66 assessable patients) were treated sequentially with doxorubicin and ifosfamide (AI), with rhTPO by a fixed dose and varying schedules being administered before and/or after chemotherapy in cycle 2 and subsequent cycles. Cycle 1 without rhTPO served as an internal control. Results: AI causes cumulative thrombocytopenia. The platelet nadir in cycle 2 was higher than in cycle 1 (mean nadir ± SEM, 119 ± 12 × 103/μL v 80 ± 7 × 103/μL, respectively; P < .001) in 24 (80%) of the 30 patients (P < .001) in whom rhTPO (1.2 μg/kg) was administered starting from 5 days before chemotherapy (pre/postdoses, three/one or one/one) compared with only four (17%) of 24 patients given rhTPO by other schedules (pre/postdoses. two/two, one/three, zero/four, or four/zero) and none of 15 historical control patients. The need for platelet transfusions in four cycles was significantly lower (13 [11%] of 114 cycles, P < .001) in patients who received rhTPO from day -5 (pre/post doses, three/one or one/one) compared with patients who received rhTPO at later time points (28 [47%] of 60 cycles). Bone marrow megakaryocytes increased markedly (four-fold) before chemotherapy with predosing rhTPO and remained elevated (two-fold) after chemotherapy, which may explain the possible mechanism for response. One patient developed subclavian vein thrombosis, and no patients developed neutralizing antibodies to rhTPO. Conclusion: These results demonstrate the importance of timing of rhTPO in relation to chemotherapy and indicate that, by optimizing the timing, only two doses of rhTPO (one before and one after chemotherapy) were required to significantly reduce the severity of chemotherapy-related early thrombocytopenia.

UR - http://www.scopus.com/inward/record.url?scp=0041411416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041411416&partnerID=8YFLogxK

U2 - 10.1200/JCO.2003.08.003

DO - 10.1200/JCO.2003.08.003

M3 - Article

C2 - 12915607

AN - SCOPUS:0041411416

VL - 21

SP - 3158

EP - 3167

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 16

ER -